<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01227824</url>
  </required_header>
  <id_info>
    <org_study_id>113086</org_study_id>
    <nct_id>NCT01227824</nct_id>
  </id_info>
  <brief_title>A Trial Comparing GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily</brief_title>
  <acronym>SPRING-2</acronym>
  <official_title>A Randomized, Double Blind Study of the Safety and Efficacy of GSK1349572 50mg Once Daily to Raltegravir 400mg Twice Daily Both Administered With Fixed-dose Dual Nucleoside Reverse Transcriptase Inhibitor Therapy Over 96 Weeks in HIV-1 Infected Antiretroviral Therapy Naive Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ViiV Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Shionogi</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>ViiV Healthcare</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this trial is to assess the non-inferior antiviral activity of GSK1349572 50
      mg once daily versus RAL 400mg twice daily over 48 weeks; non-inferiority will also be tested
      at Week 96. Both GSK1349572 and RAL will be given in combination with fixed-dose dual NRTI
      therapy (ABC/3TC or TDF/FTC). This study will be conducted in HIV-1 infected ART-naïve adult
      subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ING113086 is a Phase 3 randomized, double-blind, double dummy, active-controlled,
      multicenter, study conducted in approximately 788 HIV-1 infected ART-naïve subjects. Subjects
      will be randomized 1:1 one of the following treatment arms:

        1. GSK1349572 50 mg once daily (approximately 394 subjects) + fixed-dose dual NRTI therapy
           (either ABC/3TC or TDF/FTC)

           OR

        2. 400 mg RAL twice daily (approximately 394 subjects) + fixed-dose dual NRTI therapy
           (either ABC/3TC or TDF/FTC)

      Analyses will be conducted at 48 weeks and 96 weeks. Subjects randomized to receive
      GSK1349572 and who successfully complete 96 weeks of treatment will continue to have access
      to GSK1349572 through the study until either it is locally available, as long as they
      continue to derive clinical benefit.

      ViiV Healthcare is the new sponsor of this study, and GlaxoSmithKline is in the process of
      updating systems to reflect the change in sponsorship
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 19, 2010</start_date>
  <completion_date type="Actual">December 27, 2016</completion_date>
  <primary_completion_date type="Actual">February 6, 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] &lt;50 Copies (c)/Milliliter (mL) Through Week 48</measure>
    <time_frame>Baseline up to Week 48</time_frame>
    <description>Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with &lt;50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Detectable HIV-1 Virus That Has Genotypic or Phenotypic Evidence of INI Resistance.</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Plasma HIV-1 RNA &lt;50 c/mL</measure>
    <time_frame>Week 96</time_frame>
    <description>The number of participants with plasma HIV-1 RNA level &lt;50 c/mL was assessed at Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Plasma HIV-1 RNA &lt;400 c/mL</measure>
    <time_frame>Week 48 and Week 96</time_frame>
    <description>The number of participants with plasma HIV-1 RNA level &lt;400 c/mL was assessed at Week 48 and Week 96.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Plasma HIV-1 RNA Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
    <description>Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values in Plasma HIV-1 RNA Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
    <description>Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Baseline in Cluster of Differentiation (CD)4+ Cell Counts Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
    <description>CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Absolute Values in CD4+ Cell Counts Over Time</measure>
    <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
    <description>CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Post-Baseline HIV-associated Conditions and Progression, Excluding Recurrences</measure>
    <time_frame>From Baseline until Week 96</time_frame>
    <description>Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With the Indicated Grade 1 to 4 Clinical Chemistry and Hematology Toxicities/Laboratory Adverse Events (AEs)</measure>
    <time_frame>From Baseline until Week 96</time_frame>
    <description>All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau [AUC(0-tau)] of DTG</measure>
    <time_frame>Week 4, Week 24, and Week 48</time_frame>
    <description>AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum Plasma Concentration (Cmax) and Concentration at the End of a Dosing Interval (Ctau) of DTG</measure>
    <time_frame>Week 4, Week 24, and Week 48</time_frame>
    <description>The maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">828</enrollment>
  <condition>Infection, Human Immunodeficiency Virus I</condition>
  <arm_group>
    <arm_group_label>GSK1349572 (N=~394)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GSK1349572 50mg once daily + raltegravir placebo twice daily + NRTI background therapy once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>raltegravir (N=~394)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>raltegravir 400mg twice daily + GSK1349572 placebo once daily + NRTI background therapy once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GSK1349572 (dolutegravir)</intervention_name>
    <description>GSK1349572 50 mg taken once daily with or without food</description>
    <arm_group_label>GSK1349572 (N=~394)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>raltegravir 400mg taken twice daily</description>
    <arm_group_label>raltegravir (N=~394)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>GSK1349572 Placebo</intervention_name>
    <description>GSK1349572 placebo taken once daily</description>
    <arm_group_label>GSK1349572 (N=~394)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>ABC/3TC</intervention_name>
    <description>Abacavir/Lamivudine background therapy once daily</description>
    <arm_group_label>raltegravir (N=~394)</arm_group_label>
    <arm_group_label>GSK1349572 (N=~394)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>TDF/FTC</intervention_name>
    <description>Tenofovir/emtricitabine background therapy once daily</description>
    <arm_group_label>raltegravir (N=~394)</arm_group_label>
    <arm_group_label>GSK1349572 (N=~394)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>raltegravir Placebo</intervention_name>
    <description>raltegravir placebo taken twice daily</description>
    <arm_group_label>raltegravir (N=~394)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Screening plasma HIV-1 RNA ≥1000 c/mL

          -  Antiretroviral-naïve (≤ 10 days of prior therapy with any antiretroviral agent
             following a diagnosis of HIV-1 infection)

          -  Ability to understand and sign a written informed consent form

          -  Willingness to use approved methods of contraception to avoid pregnancy (women of
             child bearing potential only)

          -  Age equal to or greater than 18 years

        Exclusion Criteria:

          -  Women who are pregnant or breastfeeding;

          -  Active Center for Disease and Prevention Control (CDC) Category C disease

          -  Moderate to severe hepatic impairment

          -  Anticipated need for HCV therapy during the study

          -  Allergy or intolerance to the study drugs or their components or drugs of their class

          -  Malignancy within the past 5 years

          -  Treatment with an HIV-1 immunotherapeutic vaccine within 90 days of Screening

          -  Treatment with radiation therapy, cytotoxic chemotherapeutic agents or any
             immunomodulator within 28 days of Screening

          -  Exposure to an agent with documented activity against HIV-1 in vitro or an
             experimental vaccine or drug within 28 days of first dose of study medication

          -  Primary viral resistance in the Screening result

          -  Verified Grade 4 laboratory abnormality

          -  ALT &gt;5 xULN

          -  ALT ≥ 3xULN and bilirubin ≥ 1.5xULN (with &gt;35% direct bilirubin);

          -  Estimated creatinine clearance &lt;50 mL/min

          -  Recent history (≤3 months) of upper or lower gastrointestinal bleed
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>GSK Clinical Trials</last_name>
    <role>Study Director</role>
    <affiliation>ViiV Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85012</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72207</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90813</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90048</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90069</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torrance</city>
        <state>California</state>
        <zip>90502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Lauderdale</city>
        <state>Florida</state>
        <zip>33316</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fort Pierce</city>
        <state>Florida</state>
        <zip>34982</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30339</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hillsborough</city>
        <state>New Jersey</state>
        <zip>08844</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28209</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77098</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Surry Hills</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <zip>V6Z 1Y6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8N 3Z5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4N 3M5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M4T 3A7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 5B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2X 2P4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Garches</city>
        <zip>92380</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Le Kremlin Bicêtre cedex</city>
        <zip>94275</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Levallois Perret</city>
        <zip>92300</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lyon Cedex 03</city>
        <zip>69437</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Marseille</city>
        <zip>13003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 10</city>
        <zip>75475</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 12</city>
        <zip>75571</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 13</city>
        <zip>75651</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris Cedex 4</city>
        <zip>75181</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Paris</city>
        <zip>75018</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Fuerth</city>
        <state>Bayern</state>
        <zip>90762</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Muenchen</city>
        <state>Bayern</state>
        <zip>80335</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60596</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hannover</city>
        <state>Niedersachsen</state>
        <zip>30625</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Bonn</city>
        <state>Nordrhein-Westfalen</state>
        <zip>53127</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Dortmund</city>
        <state>Nordrhein-Westfalen</state>
        <zip>44137</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Koeln</city>
        <state>Nordrhein-Westfalen</state>
        <zip>50937</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20146</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Hamburg</city>
        <zip>20246</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cona (Ferrara)</city>
        <state>Emilia-Romagna</state>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Roma</city>
        <state>Lazio</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Genova</city>
        <state>Liguria</state>
        <zip>16128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brescia</city>
        <state>Lombardia</state>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Torino</city>
        <state>Piemonte</state>
        <zip>10149</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Rovigo</city>
        <state>Veneto</state>
        <zip>45100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Krasnodar</city>
        <zip>350015</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Lipetsk</city>
        <zip>398043</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Moscow</city>
        <zip>105275</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>N.Novgorod</city>
        <zip>603005</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Orel</city>
        <zip>302040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Perm</city>
        <zip>614088</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Saratov</city>
        <zip>410009</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Smolensk</city>
        <zip>214006</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>190103</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>St. Petersburg</city>
        <zip>196645</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Volgograd</city>
        <zip>400040</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>(Móstoles) Madrid</city>
        <zip>28935</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alcala de Henares</city>
        <zip>28805</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Almería</city>
        <zip>04009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Badalona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Barcelona</city>
        <zip>08907</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Cartagena (Murcia)</city>
        <zip>30202</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Granada</city>
        <zip>18014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Granada</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>La Laguna (Santa Cruz De Tenerife)</city>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28029</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28040</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Malaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Mataró</city>
        <zip>08304</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Murcia</city>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>San Sebastián</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Vigo ( Pontevedra)</city>
        <zip>36204</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Birmingham</city>
        <state>Warwickshire</state>
        <zip>B29 6JD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Brighton</city>
        <zip>BN2 1ES</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>Crumpsall, Manchester</city>
        <zip>M8 5RB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GSK Investigational Site</name>
      <address>
        <city>London</city>
        <zip>SW10 9TH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Italy</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Brinson C, Walmsley S, Arasteh K, et al. Dolutegravir treatment response and safety by key subgroups in treatment naive HIV-infected individuals. Published at: Conference on Retroviruses and Opportunistic Infections - 20th Annual; March 3-6, 2013; Atlanta, GA.</citation>
  </reference>
  <reference>
    <citation>Raffi F, Rachlis A, Stellbrink HJ, Hardy WD, Torti C, Orkin C, Bloch M, Podzamczer D, Pokrovsky V, Pulido F, Almond S, Margolis D, Brennan C, Min S; SPRING-2 Study Group. Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study. Lancet. 2013 Mar 2;381(9868):735-43. doi: 10.1016/S0140-6736(12)61853-4. Epub 2013 Jan 8.</citation>
    <PMID>23306000</PMID>
  </reference>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 14, 2010</study_first_submitted>
  <study_first_submitted_qc>October 21, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 25, 2010</study_first_posted>
  <results_first_submitted>August 15, 2013</results_first_submitted>
  <results_first_submitted_qc>June 19, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">June 23, 2014</results_first_posted>
  <disposition_first_submitted>March 21, 2013</disposition_first_submitted>
  <disposition_first_submitted_qc>March 21, 2013</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">April 1, 2013</disposition_first_posted>
  <last_update_submitted>March 8, 2018</last_update_submitted>
  <last_update_submitted_qc>March 8, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 12, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>integrase inhibitor</keyword>
  <keyword>HIV Infection</keyword>
  <keyword>raltegravir</keyword>
  <keyword>GSK1349572</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Immunologic Deficiency Syndromes</mesh_term>
    <mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Dolutegravir</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>This was a randomized, parallel group, non-inferiority study to demonstrate the antiviral activity of Dolutegravir. Participants were enrolled from 9 countries. Participants in Dolutegravir arm who completed 96 Weeks double-blind phase continued to receive Dolutegravir in open-label phase, until dolutegravir was locally available commercially.</recruitment_details>
      <pre_assignment_details>Total 1035 participants were screened; 827 participants were randomized, and 822 participants entered the treatment period. Of the 5 participants who were randomized but not treated with investigational product, 4 withdrew consent and 1 was randomized in error. 338 participants were enrolled in open label phase to receive Dolutegravir.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>DTG 50 mg Once a Day</title>
          <description>Participants received Dolutegravir (DTG) 50 milligrams (mg) once a day in combination with Nonnucleoside Reverse Transcriptase Inhibitor (NRTI) therapy, either with Abacavir (ABC)/Lamivudine (3TC) or Tenofovir (TDF)/Emtricitabine (FTC). Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
        </group>
        <group group_id="P2">
          <title>RTG 400 mg BID</title>
          <description>Participants received Raltegravir (RTG) 400 mg twice a day (BID) in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
        </group>
        <group group_id="P3">
          <title>DTG 50 mg Once a Day (Open-label)</title>
          <description>Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until dolutegravir was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Double-blind Phase: 96 Weeks Duration</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="411"/>
                <participants group_id="P2" count="411"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="304"/>
                <participants group_id="P2" count="332"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="107"/>
                <participants group_id="P2" count="79"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="12"/>
                <participants group_id="P2" count="7"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="25"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="3"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Study Closed/Terminated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="14"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Open-label Phase: Median of 1267 Days</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="338">338 participants continued into the Open-label phase on completing the Double-blind Phase</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="294"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="44"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="5"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Met Protocol-defined Stopping Criteria</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="15"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="8"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>DTG 50 mg Once a Day</title>
          <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF)/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
        </group>
        <group group_id="B2">
          <title>RTG 400 mg BID</title>
          <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="411"/>
            <count group_id="B2" value="411"/>
            <count group_id="B3" value="822"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="37.3" spread="9.19"/>
                    <measurement group_id="B2" value="36.6" spread="10.02"/>
                    <measurement group_id="B3" value="37.0" spread="9.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="56"/>
                    <measurement group_id="B3" value="119"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="348"/>
                    <measurement group_id="B2" value="355"/>
                    <measurement group_id="B3" value="703"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>African American/African Heritage (Her)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="49"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>American Indian or Alaska Native</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Central/South Asian Her</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese/East Asian Her/South East Asian Her</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Native Hawaiian or other Pacific Islander</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="346"/>
                    <measurement group_id="B2" value="352"/>
                    <measurement group_id="B3" value="698"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American/African Her and Asian and White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian and White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] &lt;50 Copies (c)/Milliliter (mL) Through Week 48</title>
        <description>Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with &lt;50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication.</description>
        <time_frame>Baseline up to Week 48</time_frame>
        <population>ITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) [HIV-1RNA] &lt;50 Copies (c)/Milliliter (mL) Through Week 48</title>
          <description>Percentage of participants with plasma Human Immunodeficiency Virus-1 (HIV-1) Ribonucleic Acid (RNA) with &lt;50 c/mL was assessed using the Missing, Switch or Discontinuation = Failure (MSDF), as codified by the Food and Drug Administration (FDA) snapshot algorithm. The algorithm treats all participants without HIV-1 RNA data as non-responders, as well as participants who switch their concomitant Antiretroviral Therapy (ART) prior to Week 48 as follows: background ART substitutions not permitted per study; background ART substitutions permitted per study unless the decision to switch was documented as being before or at the first on-treatment visit where HIV-1 RNA was assessed. Otherwise, virologic success or failure will be determined by the last available HIV-1 RNA assessment while the subject was on-treatment. Intent-to-Treat Exposed (ITT-E) Population comprised all randomized participants who received at least one dose of study medication.</description>
          <population>ITT-E Population.</population>
          <units>Percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="88"/>
                    <measurement group_id="O2" value="85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Non-Inferiority or Equivalence</non_inferiority_type>
            <non_inferiority_desc>Non-inferiority could be concluded if the lower bound of a two-sided 95% confidence interval for the difference (DTG - RAL) in percentages between the two treatment arms was &gt; -10%.</non_inferiority_desc>
            <param_type>Difference in percentage</param_type>
            <param_value>2.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.2</ci_lower_limit>
            <ci_upper_limit>7.1</ci_upper_limit>
            <estimate_desc>Analysis was based on Cochran-Mantel Haenszel stratified analysis adjusted for the following Baseline stratification factors: baseline HIV-1 RNA and background dual NRTI.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Detectable HIV-1 Virus That Has Genotypic or Phenotypic Evidence of INI Resistance.</title>
        <description>Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell.</description>
        <time_frame>Week 48 and Week 96</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Detectable HIV-1 Virus That Has Genotypic or Phenotypic Evidence of INI Resistance.</title>
          <description>Number of participants with detectable virus that has genotypic or phenotypic evidence of Integrase Inhibitor (INI) resistance were assessed at Week 48 and Week 96. Integrase inhibitors are a class of antiretroviral drug designed to block the action of integrase, a viral enzyme that inserts the viral genome into the deoxyribonucleic acid (DNA) of the host cell.</description>
          <population>ITT-E Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48, genotypic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, phenotypic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, genotypic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, phenotypic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Plasma HIV-1 RNA &lt;50 c/mL</title>
        <description>The number of participants with plasma HIV-1 RNA level &lt;50 c/mL was assessed at Week 96.</description>
        <time_frame>Week 96</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma HIV-1 RNA &lt;50 c/mL</title>
          <description>The number of participants with plasma HIV-1 RNA level &lt;50 c/mL was assessed at Week 96.</description>
          <population>ITT-E Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="332"/>
                    <measurement group_id="O2" value="314"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Plasma HIV-1 RNA &lt;400 c/mL</title>
        <description>The number of participants with plasma HIV-1 RNA level &lt;400 c/mL was assessed at Week 48 and Week 96.</description>
        <time_frame>Week 48 and Week 96</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Plasma HIV-1 RNA &lt;400 c/mL</title>
          <description>The number of participants with plasma HIV-1 RNA level &lt;400 c/mL was assessed at Week 48 and Week 96.</description>
          <population>ITT-E Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Week 48</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="369"/>
                    <measurement group_id="O2" value="356"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="338"/>
                    <measurement group_id="O2" value="321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Plasma HIV-1 RNA Over Time</title>
        <description>Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
        <population>ITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Plasma HIV-1 RNA Over Time</title>
          <description>Change from Baseline in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as the measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
          <population>ITT-E Population.</population>
          <units>log10 c/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline n=411, 411</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.538" spread="0.7258"/>
                    <measurement group_id="O2" value="4.599" spread="0.7048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=402, 406</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="402"/>
                    <count group_id="O2" value="406"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.817" spread="0.6198"/>
                    <measurement group_id="O2" value="-2.801" spread="0.6041"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=397, 402</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.897" spread="0.6837"/>
                    <measurement group_id="O2" value="-2.886" spread="0.6754"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=396, 395</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.908" spread="0.6863"/>
                    <measurement group_id="O2" value="-2.918" spread="0.6834"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=395, 388</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.917" spread="0.6949"/>
                    <measurement group_id="O2" value="-2.943" spread="0.6841"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=393, 390</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.896" spread="0.7889"/>
                    <measurement group_id="O2" value="-2.933" spread="0.7398"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, n=386, 377</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.907" spread="0.7609"/>
                    <measurement group_id="O2" value="-2.947" spread="0.7613"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, n=375, 358</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.920" spread="0.7219"/>
                    <measurement group_id="O2" value="-2.946" spread="0.6700"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=374, 358</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.915" spread="0.7237"/>
                    <measurement group_id="O2" value="-2.942" spread="0.6737"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60, n=366, 355</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.912" spread="0.7344"/>
                    <measurement group_id="O2" value="-2.937" spread="0.6685"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72, n=361, 350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.917" spread="0.7261"/>
                    <measurement group_id="O2" value="-2.932" spread="0.6728"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84, n=352, 338</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.932" spread="0.7073"/>
                    <measurement group_id="O2" value="-2.916" spread="0.6646"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=342, 329</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.938" spread="0.7004"/>
                    <measurement group_id="O2" value="-2.901" spread="0.7072"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values in Plasma HIV-1 RNA Over Time</title>
        <description>Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
        <population>ITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values in Plasma HIV-1 RNA Over Time</title>
          <description>Absolute values in plasma HIV-1 RNA over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
          <population>ITT-E Population.</population>
          <units>log10 c/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline n=411, 411</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.538" spread="0.7258"/>
                    <measurement group_id="O2" value="4.599" spread="0.7048"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=402, 406</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="402"/>
                    <count group_id="O2" value="406"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.718" spread="0.2593"/>
                    <measurement group_id="O2" value="1.800" spread="0.4095"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=397, 402</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="397"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.646" spread="0.2006"/>
                    <measurement group_id="O2" value="1.709" spread="0.3791"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=396, 395</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="396"/>
                    <count group_id="O2" value="395"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.626" spread="0.1323"/>
                    <measurement group_id="O2" value="1.672" spread="0.3125"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=395, 388</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="395"/>
                    <count group_id="O2" value="388"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.620" spread="0.1252"/>
                    <measurement group_id="O2" value="1.648" spread="0.2647"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=393, 390</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="393"/>
                    <count group_id="O2" value="390"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.643" spread="0.2950"/>
                    <measurement group_id="O2" value="1.655" spread="0.3476"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, n=386, 377</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="386"/>
                    <count group_id="O2" value="377"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.620" spread="0.1917"/>
                    <measurement group_id="O2" value="1.636" spread="0.2721"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, n=375, 358</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="375"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.603" spread="0.0821"/>
                    <measurement group_id="O2" value="1.601" spread="0.0784"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=374, 358</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="358"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.606" spread="0.0866"/>
                    <measurement group_id="O2" value="1.599" spread="0.0582"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60, n=366, 355</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="366"/>
                    <count group_id="O2" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.605" spread="0.1134"/>
                    <measurement group_id="O2" value="1.599" spread="0.0560"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72, n=361, 350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="361"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.601" spread="0.0803"/>
                    <measurement group_id="O2" value="1.605" spread="0.0836"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84, n=352, 338</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="352"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.607" spread="0.1337"/>
                    <measurement group_id="O2" value="1.614" spread="0.1279"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=342, 329</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="342"/>
                    <count group_id="O2" value="329"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.599" spread="0.830"/>
                    <measurement group_id="O2" value="1.630" spread="0.2515"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Baseline in Cluster of Differentiation (CD)4+ Cell Counts Over Time</title>
        <description>CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
        <population>ITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Baseline in Cluster of Differentiation (CD)4+ Cell Counts Over Time</title>
          <description>CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the participants disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start ART. Changes from Baseline in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Baseline was defined as measurements performed on Day 1. Change from Baseline was calculated as the post-Baseline value minus the Baseline value. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
          <population>ITT-E Population.</population>
          <units>Cells per cubic millimeter (cells/mm^3)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline n=411, 411</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.2" spread="178.32"/>
                    <measurement group_id="O2" value="374.3" spread="163.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=398, 403</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="93.3" spread="116.27"/>
                    <measurement group_id="O2" value="97.2" spread="129.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=398, 402</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="121.6" spread="127.97"/>
                    <measurement group_id="O2" value="126.6" spread="134.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=392, 397</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="130.7" spread="131.49"/>
                    <measurement group_id="O2" value="145.1" spread="144.08"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=394, 392</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="155.1" spread="137.23"/>
                    <measurement group_id="O2" value="173.0" spread="159.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=392, 389</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="199.3" spread="161.23"/>
                    <measurement group_id="O2" value="204.2" spread="162.28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, n=384, 375</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="375"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="223.4" spread="165.30"/>
                    <measurement group_id="O2" value="241.3" spread="167.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, n=371, 357</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="224.1" spread="173.59"/>
                    <measurement group_id="O2" value="239.8" spread="173.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=374, 357</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="238.9" spread="171.81"/>
                    <measurement group_id="O2" value="257.5" spread="178.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60, n=367, 355</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.8" spread="184.11"/>
                    <measurement group_id="O2" value="264.2" spread="188.63"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72, n=360, 350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="247.8" spread="168.37"/>
                    <measurement group_id="O2" value="278.6" spread="182.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84, n=351, 338</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="281.3" spread="175.07"/>
                    <measurement group_id="O2" value="292.9" spread="199.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=343, 328</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="292.2" spread="195.70"/>
                    <measurement group_id="O2" value="286.2" spread="192.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Values in CD4+ Cell Counts Over Time</title>
        <description>CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
        <time_frame>Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96</time_frame>
        <population>ITT-E Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Values in CD4+ Cell Counts Over Time</title>
          <description>CD4 lymphocyte cells (also called T-cells or T-helper cells) are the primary targets of HIV. The CD4 count and the CD4 percentage mark the degree of immuno compromise. The CD4 count is used to stage the patient's disease, determine the risk of opportunistic illnesses, assess prognosis, and guide decisions about when to start antiretroviral therapy absolute values in CD4+ cell counts over time was assessed at Baseline and Weeks 4, 8, 12, 16, 24, 32, 40, 48, 60, 72, 84, 96. Only those participants with data available at the specified time points were analyzed (represented by n=x,x in the category titles).</description>
          <population>ITT-E Population.</population>
          <units>cells/mm^3</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline n=411, 411</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="411"/>
                    <count group_id="O2" value="411"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="379.2" spread="172.32"/>
                    <measurement group_id="O2" value="374.3" spread="163.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 4, n=398, 403</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="403"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="474.2" spread="199.06"/>
                    <measurement group_id="O2" value="471.8" spread="191.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 8, n=398, 402</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="398"/>
                    <count group_id="O2" value="402"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="502.3" spread="205.15"/>
                    <measurement group_id="O2" value="502.4" spread="187.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12, n=392, 397</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="397"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="513.3" spread="218.75"/>
                    <measurement group_id="O2" value="518.3" spread="195.59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 16, n=394, 392</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="394"/>
                    <count group_id="O2" value="392"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="536.4" spread="219.47"/>
                    <measurement group_id="O2" value="550.1" spread="221.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 24, n=392, 389</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="392"/>
                    <count group_id="O2" value="389"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="582.0" spread="232.93"/>
                    <measurement group_id="O2" value="580.8" spread="218.76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 32, n=384, 375</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="384"/>
                    <count group_id="O2" value="375"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="606.5" spread="242.95"/>
                    <measurement group_id="O2" value="618.7" spread="237.56"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 40, n=371, 357</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="371"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="609.1" spread="239.11"/>
                    <measurement group_id="O2" value="623.1" spread="234.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 48, n=374, 357</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="374"/>
                    <count group_id="O2" value="357"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="623.8" spread="247.82"/>
                    <measurement group_id="O2" value="641.2" spread="241.75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 60, n=367, 355</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="367"/>
                    <count group_id="O2" value="355"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635.6" spread="241.27"/>
                    <measurement group_id="O2" value="648.5" spread="238.99"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 72, n=360, 350</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="360"/>
                    <count group_id="O2" value="350"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="635.2" spread="237.78"/>
                    <measurement group_id="O2" value="664.0" spread="239.86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 84, n=351, 338</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="351"/>
                    <count group_id="O2" value="338"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="668.0" spread="246.50"/>
                    <measurement group_id="O2" value="677.5" spread="249.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 96, n=343, 328</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="343"/>
                    <count group_id="O2" value="328"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="679.8" spread="257.89"/>
                    <measurement group_id="O2" value="672.4" spread="237.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Post-Baseline HIV-associated Conditions and Progression, Excluding Recurrences</title>
        <description>Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.</description>
        <time_frame>From Baseline until Week 96</time_frame>
        <population>ITT-E Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Post-Baseline HIV-associated Conditions and Progression, Excluding Recurrences</title>
          <description>Clinical disease progression (CDP) was assessed according to the Centers for Disease Control and Prevention (CDC) HIV-1 classification system. Category (CAT) A: one or more of the following conditions (CON), without any CON listed in Categories B and C: asymptomatic HIV infection, persistent generalized lymphadenopathy, acute (primary) HIV infection with accompanying illness or history of acute HIV infection. CAT B: symptomatic CON that are attributed to HIV infection or are indicative of a defect in cell-mediated immunity; or that are considered by physicians to have a clinical course or to require management that is complicated by HIV infection; and not included among CON listed in clinical CAT C. CAT C: the clinical CON listed in the AIDS surveillance case definition. Indicators of CDP were defined as: CDC CAT A at Baseline to a CDC CAT C event (EV); CDC CAT B at Baseline to a CDC CAT C EV; CDC CAT C at Baseline to a new CDC CAT C EV; or CDC CAT A, B, or C at Baseline to death.</description>
          <population>ITT-E Population</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any category condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Category B condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any Category C condition</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Any death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression from CAT A to CAT C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression from CAT B to CAT C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression from CAT C to new CAT C</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Progression from CAT A, B, or C to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With the Indicated Grade 1 to 4 Clinical Chemistry and Hematology Toxicities/Laboratory Adverse Events (AEs)</title>
        <description>All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product</description>
        <time_frame>From Baseline until Week 96</time_frame>
        <population>Safety Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With the Indicated Grade 1 to 4 Clinical Chemistry and Hematology Toxicities/Laboratory Adverse Events (AEs)</title>
          <description>All Grade 1 to 4 post-Baseline-emergent chemistry toxicities included alanine aminotransferase (ALT), alkaline phosphatase (ALP), asparate aminotransferase (AST), carbon dioxide (CO2) content/bicarbonate, cholesterol, creatine kinase (CK), creatinine, hyperglycemia, hyperkalemia, hypernatremia, hypoglycemia, hypokalemia, hyponatremia, low density lipoprotein (LDL) cholesterol calculation, lipase, phosphorus inorganic, total bilirubin, and triglycerides. All Grade 1 to 4 post-Baseline-emergent hematology toxities included hemoglobin, platelet count, total neutrophils, and white blood cell count. The Division of AIDS (DAIDS) defined toxicity grades as follows: Grade 1, mild; Grade 2, moderate; Grade 3, severe; Grade 4, potentially life threatening; Grade 5, death. Safety Population: all participants who received at least one dose of investigational product</description>
          <population>Safety Population.</population>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="411"/>
                <count group_id="O2" value="411"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>ALT</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="57"/>
                    <measurement group_id="O2" value="70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>ALP</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AST</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="67"/>
                    <measurement group_id="O2" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CO2 content/bicarbonate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="58"/>
                    <measurement group_id="O2" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Cholesterol</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90"/>
                    <measurement group_id="O2" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CK</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="61"/>
                    <measurement group_id="O2" value="47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Creatinine</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperglycaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70"/>
                    <measurement group_id="O2" value="87"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyperkalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypernatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypoglycaemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="17"/>
                    <measurement group_id="O2" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hypokalemia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hyponatremia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LDL cholesterol calculation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74"/>
                    <measurement group_id="O2" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Lipase</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="55"/>
                    <measurement group_id="O2" value="62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Phosphorus, inorganic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="65"/>
                    <measurement group_id="O2" value="71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total bilirubin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Triglycerides</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hemoglobin</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10"/>
                    <measurement group_id="O2" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Platelet count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total neutrophils</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="54"/>
                    <measurement group_id="O2" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White Blood Cell count</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19"/>
                    <measurement group_id="O2" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau [AUC(0-tau)] of DTG</title>
        <description>AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.</description>
        <time_frame>Week 4, Week 24, and Week 48</time_frame>
        <population>PK Concentration Population</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Area Under the Plasma Concentration-time Curve From Time Zero to Time Tau [AUC(0-tau)] of DTG</title>
          <description>AUC is defined as the area under the DTG concentration-time curve as a measure of drug exposure over time. AUC(0-tau) is defined as the area under the plasma concentration-time curve from time zero to time tau over a dosing interval at steady state, where tau is the length of the dosing interval of DTG. The predicted individual AUC(0-tau) were obtained from the final population PK model by an empirical Bayes estimation. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hours post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa. The Pharmacokinetic (PK) Concentration Population comprised of all participants who received DTG, had undergone PK sampling during the study, and provided evaluable DTG plasma concentration data.</description>
          <population>PK Concentration Population</population>
          <units>Micrograms*hour per milliliter(µg*hr/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.6" spread="26.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Maximum Plasma Concentration (Cmax) and Concentration at the End of a Dosing Interval (Ctau) of DTG</title>
        <description>The maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa.</description>
        <time_frame>Week 4, Week 24, and Week 48</time_frame>
        <population>PK Concentration Population.</population>
        <group_list>
          <group group_id="O1">
            <title>DTG 50 mg Once a Day</title>
            <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
          </group>
          <group group_id="O2">
            <title>RTG 400 mg BID</title>
            <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
          </group>
        </group_list>
        <measure>
          <title>Maximum Plasma Concentration (Cmax) and Concentration at the End of a Dosing Interval (Ctau) of DTG</title>
          <description>The maximum plasma concentration (Cmax) and concentration at the end of a dosing interval (Ctau) of DTG were assessed at Week 48. The predicted individual Cmax and Ctau were obtained from the final population PK model by simulation of the concentration-time profiles. Blood samples for PK assessments were collected at pre-dose (within 15 minutes prior to dose) at Week 4, Week 24, and Week 48 and 1 to 3 hours post-dose or 4 to 12 hours post-dose at Week 4 and Week 24. If 1 to 3 hour post-dose was completed at Week 4, then the 4 to12 hour post-dose must be obtained at Week 48, and vice versa.</description>
          <population>PK Concentration Population.</population>
          <units>Micrograms per milliliter (µg/mL)</units>
          <param>Geometric Mean</param>
          <dispersion>Geometric Coefficient of Variation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="403"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Cmax</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.69" spread="19.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Ctau</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="46.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Serious adverse events (SAEs) and non-serious AEs were collected from the start of study medication to the end of the study (up to a median of 1267 days).</time_frame>
      <desc>AEs and non-serious AEs were collected in members of the Safety Population, comprised of all participants who received at least one dose of investigational product.</desc>
      <group_list>
        <group group_id="E1">
          <title>DTG 50 mg Once a Day</title>
          <description>Participants received DTG 50 mg once a day in combination with NRTI therapy, either with ABC/3TC or TDF/FTC. Participants were given the opportunity to receive DTG 50 mg once a day during an Open-label Phase of the study.</description>
        </group>
        <group group_id="E2">
          <title>RTG 400mg BID</title>
          <description>Participants received RTG 400 mg BID in combination with NRTI therapy, either with ABC/3TC or TDF/FTC.</description>
        </group>
        <group group_id="E3">
          <title>DTG 50 mg Once a Day (Open-label)</title>
          <description>Participants who successfully completed 96 weeks of double blind phase continued to receive DTG 50 mg once a day during open label phase, until DTG was locally available commercially. Participants received DTG 50 mg once a day in combination with NRTI therapy, with either ABC/3TC or TDF/FTC.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="41" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="45" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="21" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Arrhythmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancreatic pseudocyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctitis ulcerative</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Polyserositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatotoxicity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Portal vein thrombosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthritis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Atypical mycobacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Corneal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Encephalitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lymphadenitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Meningitis tuberculous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neurosyphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteomyelitis chronic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumocystis jirovecii pneumonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alcohol poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intentional overdose</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Multiple fractures</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Penis injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post procedural haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tibia fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Toxicity to various agents</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung neoplasm malignant</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Breast cancer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Malignant melanoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Metastatic malignant melanoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Transitional cell carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Aphasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebrovascular accident</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Status epilepticus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Suicide attempt</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Completed suicide</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia aspiration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Homicide</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Keratoplasty</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA 20.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="353" subjects_at_risk="411"/>
                <counts group_id="E2" subjects_affected="344" subjects_at_risk="411"/>
                <counts group_id="E3" subjects_affected="256" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Lymphadenopathy</sub_title>
                <counts group_id="E1" events="13" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Iron deficiency anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lymphadenitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eosinophilia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Granulocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Polycythaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Red blood cell abnormality</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thymus disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Angina pectoris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Palpitations</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cardiomyopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Myocarditis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ventricular hypokinesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Hereditary non-polyposis colorectal cancer syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ichthyosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Kidney duplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Odontogenic cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ear pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypoacusis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Deafness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ear disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eustachian tube obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Excessive cerumen production</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>External ear inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>External ear pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Middle ear effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tympanic membrane disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Hypothyroidism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Goitre</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Androgen deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Basedow's disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperthyroidism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thyroid mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Vision blurred</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Conjunctivitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ocular hyperaemia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Visual acuity reduced</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chalazion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Conjunctival haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Conjunctival hyperaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dry eye</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye pruritus</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blepharitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Corneal erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eyelids pruritus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypermetropia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Keratitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ocular discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Photophobia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Retinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Retinal tear</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scleritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="72" subjects_affected="58" subjects_at_risk="411"/>
                <counts group_id="E2" events="65" subjects_affected="54" subjects_at_risk="411"/>
                <counts group_id="E3" events="25" subjects_affected="21" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="70" subjects_affected="60" subjects_at_risk="411"/>
                <counts group_id="E2" events="66" subjects_affected="55" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E2" events="20" subjects_affected="16" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="21" subjects_affected="16" subjects_at_risk="411"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" events="16" subjects_affected="15" subjects_at_risk="411"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" events="13" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" events="15" subjects_affected="15" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" events="12" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Toothache</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anogenital dysplasia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal discomfort</sub_title>
                <counts group_id="E1" events="11" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal fissure</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Aphthous ulcer</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Odynophagia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rectal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dental caries</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal pain lower</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Enteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Inguinal hernia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal fistula</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hiatus hernia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal pruritus</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mouth ulceration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abnormal faeces</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal ulcer</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anorectal discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysphagia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Food poisoning</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haematochezia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haemorrhoidal haemorrhage</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oesophageal spasm</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abdominal rigidity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal skin tags</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal spasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anorectal disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diverticulum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Epigastric discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Erosive duodenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Faeces pale</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastric ulcer</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gingival hypertrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gingival pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gingival swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haemorrhoids thrombosed</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperchlorhydria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Irritable bowel syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Large intestine polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lip haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lip swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Loose tooth</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mouth cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oesophageal pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Palatal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Palatal ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pancreatitis acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Paraesthesia oral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Periodontal disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rectal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rectal fissure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Saliva altered</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Salivary hypersecretion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Stomatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tongue disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tooth disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tooth impacted</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ulcerative gastritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="26" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E2" events="27" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="30" subjects_affected="23" subjects_at_risk="411"/>
                <counts group_id="E2" events="26" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" events="16" subjects_affected="14" subjects_at_risk="411"/>
                <counts group_id="E2" events="19" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Influenza like illness</sub_title>
                <counts group_id="E1" events="15" subjects_affected="13" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chest pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Feeling abnormal</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Malaise</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Local swelling</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chest discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Granuloma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ill-defined disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Inflammation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mucosal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nodule</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Suprapubic pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Axillary pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chills</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Facial pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Feeling cold</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mucosal inflammation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oedema mucosal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Polyp</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic steatosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholelithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis toxic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Biliary colic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Drug-induced liver injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gallbladder polyp</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatic cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatic lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatocellular injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatomegaly</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Seasonal allergy</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Food allergy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Drug hypersensitivity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Immune reconstitution inflammatory syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Jarisch-Herxheimer reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="73" subjects_affected="54" subjects_at_risk="411"/>
                <counts group_id="E2" events="77" subjects_affected="54" subjects_at_risk="411"/>
                <counts group_id="E3" events="27" subjects_affected="24" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="43" subjects_affected="34" subjects_at_risk="411"/>
                <counts group_id="E2" events="38" subjects_affected="31" subjects_at_risk="411"/>
                <counts group_id="E3" events="36" subjects_affected="27" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Syphilis</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E2" events="30" subjects_affected="28" subjects_at_risk="411"/>
                <counts group_id="E3" events="30" subjects_affected="24" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="33" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E2" events="25" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E3" events="16" subjects_affected="15" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sinusitis</sub_title>
                <counts group_id="E1" events="36" subjects_affected="25" subjects_at_risk="411"/>
                <counts group_id="E2" events="18" subjects_affected="16" subjects_at_risk="411"/>
                <counts group_id="E3" events="19" subjects_affected="12" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="21" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E2" events="23" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E3" events="11" subjects_affected="10" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="31" subjects_affected="23" subjects_at_risk="411"/>
                <counts group_id="E2" events="16" subjects_affected="14" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="411"/>
                <counts group_id="E2" events="23" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E2" events="14" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="20" subjects_affected="13" subjects_at_risk="411"/>
                <counts group_id="E2" events="15" subjects_affected="13" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral herpes</sub_title>
                <counts group_id="E1" events="9" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" events="17" subjects_affected="13" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Conjunctivitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary tract infection</sub_title>
                <counts group_id="E1" events="14" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory tract infection viral</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethritis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chlamydial infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="13" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gonorrhoea</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Herpes zoster</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gingivitis</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tonsillitis</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Folliculitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ear infection</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genital herpes</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" events="8" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Secondary syphilis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Herpes virus infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Onychomycosis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fungal skin infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethritis gonococcal</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Otitis externa</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tooth abscess</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tinea infection</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal chlamydia infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lymphogranuloma venereum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Otitis media</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tinea versicolour</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acarodermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Laryngitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal abscess</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Erysipelas</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genital infection fungal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Labyrinthitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctitis gonococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tinea cruris</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fungal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Orchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash pustular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Staphylococcal infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tinea pedis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" events="4" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute hepatitis C</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Balanitis candida</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cystitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Epididymitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Giardiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Helicobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hordeolum</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Localised infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lung infection</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Parotitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Primary syphilis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tracheitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Angular cheilitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Beta haemolytic streptococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervicitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermatophytosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis shigella</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genital herpes simplex</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genital infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Helicobacter gastritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis A</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis C</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infected bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infection parasitic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Molluscum contagiosum</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Parasitic gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Paronychia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctitis chlamydial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abscess oral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Amoebiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Asymptomatic bacteriuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacterial disease carrier</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacterial infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bacteriuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Body tinea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Campylobacter gastroenteritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Campylobacter infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Carbuncle</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervicitis human papilloma virus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic hepatitis C</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic tonsillitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Clostridium difficile colitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Conjunctivitis viral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysentery</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ear infection fungal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Enterobiasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Enterovirus infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastroenteritis clostridial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gastrointestinal viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genitourinary chlamydia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genitourinary tract infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Groin abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis E</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hepatitis viral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Impetigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Infected cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Latent syphilis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lung abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nail infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ophthalmic herpes simplex</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral viral infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oropharyngeal gonococcal infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Papilloma viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pericoronitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Periorbital cellulitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peritonsillar abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pharyngitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumonia cytomegaloviral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post procedural infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proctitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pulpitis dental</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyelonephritis chronic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pyuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scrotal abscess</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sexually transmitted disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sialoadenitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sinobronchitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sycosis barbae</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tonsillitis bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tonsillitis streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethritis chlamydial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary tract infection bacterial</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vaginitis gardnerella</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Viral pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vulvovaginal candidiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Yersinia infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Ligament sprain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Limb injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Epicondylitis</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Laceration</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rib fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin abrasion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bone contusion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Foot fracture</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Meniscus injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Back injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Concussion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Exposure to communicable disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hand fracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ligament rupture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post-traumatic neck syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Procedural pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Road traffic accident</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scar</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tendon rupture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thermal burn</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Accident</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Animal bite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ankle fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthropod sting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bone fissure</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Burns second degree</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cartilage injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ear injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye contusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Head injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Human bite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Joint dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Joint injury</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lower limb fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neck injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Patella fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Penis injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post lumbar puncture syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post procedural discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post-traumatic pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scratch</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Subdural haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tendon injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Traumatic haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ulnar nerve injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Wound</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Weight increased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" events="4" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood pressure increased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood creatine phosphokinase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lipase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood creatinine increased</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood glucose increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary sediment present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood alkaline phosphatase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood bilirubin increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood cholesterol increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood glucose decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood phosphorus decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood testosterone decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Blood thyroid stimulating hormone increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Heart sounds abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Human papilloma virus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Liver function test increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oestradiol increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Parasite stool test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Protein urine present</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>QRS axis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Shigella test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Streptococcus test positive</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urine analysis abnormal</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Vitamin D deficiency</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypophosphataemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypercholesterolaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperlipidaemia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dyslipidaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Increased appetite</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alcohol intolerance</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Body fat disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Diabetes mellitus inadequate control</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Folate deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Food intolerance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperlipasaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypertriglyceridaemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypovitaminosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lactase deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Obesity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Polydipsia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Type 2 diabetes mellitus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vitamin B12 deficiency</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="27" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E2" events="29" subjects_affected="26" subjects_at_risk="411"/>
                <counts group_id="E3" events="15" subjects_affected="10" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="13" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E2" events="17" subjects_affected="14" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tendonitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="10" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="11" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteopenia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neck pain</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bursitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteoporosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Spinal osteoarthritis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Joint swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Muscle contracture</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Plantar fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Synovial cyst</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intervertebral disc disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Limb discomfort</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Musculoskeletal discomfort</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Musculoskeletal stiffness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rotator cuff syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Spinal pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bone erosion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Bone pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Costochondritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dupuytren's contracture</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Enthesopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fasciitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fistula</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Foot deformity</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gouty arthritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Groin pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intervertebral disc degeneration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Jaw disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Joint stiffness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Muscle fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Muscle tightness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Muscle twitching</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Myosclerosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Myositis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteochondrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Osteonecrosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Periarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Plantar fascial fibromatosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Psoriatic arthropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scoliosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Torticollis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Anogenital warts</sub_title>
                <counts group_id="E1" events="17" subjects_affected="16" subjects_at_risk="411"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="8" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin papilloma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fibroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acrochordon</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Kaposi's sarcoma</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Melanocytic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Basal cell carcinoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oral papilloma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Seborrhoeic keratosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anal neoplasm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervix carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysplastic naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eye haemangioma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fibroadenoma of breast</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Fibrous histiocytoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haemangioma of liver</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haemangioma of spleen</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Keratoacanthoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Papilloma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Penile wart</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Schwannoma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Uterine leiomyoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="63" subjects_affected="56" subjects_at_risk="411"/>
                <counts group_id="E2" events="70" subjects_affected="55" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" events="25" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E2" events="24" subjects_affected="24" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="7" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Disturbance in attention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Facial paralysis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Amnesia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervicobrachial syndrome</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Memory impairment</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Balance disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Burning sensation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cognitive disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysaesthesia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neuropathy peripheral</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Poor quality sleep</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Agnosia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anosmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Apraxia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Brain injury</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cerebral haemorrhage</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervical radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Circadian rhythm sleep disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cluster headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dizziness postural</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dystonia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperaesthesia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Morton's neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nerve compression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peripheral sensory neuropathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Peroneal nerve palsy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post herpetic neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sensory disturbance</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Trigeminal neuralgia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vascular headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" events="28" subjects_affected="28" subjects_at_risk="411"/>
                <counts group_id="E2" events="20" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" events="26" subjects_affected="26" subjects_at_risk="411"/>
                <counts group_id="E2" events="18" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E3" events="8" subjects_affected="8" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="19" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Abnormal dreams</sub_title>
                <counts group_id="E1" events="14" subjects_affected="13" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sleep disorder</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Libido decreased</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Stress</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nightmare</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Depressed mood</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Panic attack</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acute stress disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Drug use disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Burnout syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Euphoric mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Irritability</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Suicidal ideation</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Emotional disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Adjustment disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Adjustment disorder with depressed mood</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Aggression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Agoraphobia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alcohol withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alcoholic psychosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Anxiety disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Apathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Attention deficit/hyperactivity disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Confusional state</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Major depression</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mental disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mental fatigue</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Middle insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mood swings</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nervousness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Panic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Persistent depressive disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Phobia of flying</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sleep-related eating disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Somnambulism</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Substance-induced psychotic disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Terminal insomnia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thinking abnormal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Withdrawal syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Dysuria</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethral discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Micturition urgency</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Leukocyturia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethral pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic kidney disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pollakiuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Polyuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Proteinuria</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal colic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Glycosuria</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Microalbuminuria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Renal impairment</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tubulointerstitial nephritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethral haemorrhage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urethral stenosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary hesitation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary retention</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urinary tract disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urine flow decreased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Erectile dysfunction</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="411"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Benign prostatic hyperplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cervical dysplasia</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Gynaecomastia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sexual dysfunction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vaginal discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Balanoposthitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Breast mass</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Breast pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Endometriosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Epididymal tenderness</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genital lesion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Genital rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hypospermia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Menstruation irregular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Ovarian cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pelvic discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Penile discharge</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Prostatomegaly</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scrotal swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Testicular oedema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Testicular swelling</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Testis discomfort</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Varicocele</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vulval ulceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="27" subjects_affected="23" subjects_at_risk="411"/>
                <counts group_id="E2" events="24" subjects_affected="22" subjects_at_risk="411"/>
                <counts group_id="E3" events="9" subjects_affected="9" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="22" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E2" events="19" subjects_affected="16" subjects_at_risk="411"/>
                <counts group_id="E3" events="7" subjects_affected="6" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Asthma</sub_title>
                <counts group_id="E1" events="10" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rhinitis allergic</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="13" subjects_affected="11" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Catarrh</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Allergic sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Chronic obstructive pulmonary disease</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dysphonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lung disorder</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tonsillar hypertrophy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Atelectasis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dry throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Emphysema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Laryngospasm</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nasal dryness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nasal obstruction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nocturnal dyspnoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Sleep apnoea syndrome</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Upper-airway cough syndrome</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="22" subjects_affected="18" subjects_at_risk="411"/>
                <counts group_id="E2" events="23" subjects_affected="19" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pruritus</sub_title>
                <counts group_id="E1" events="18" subjects_affected="17" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="411"/>
                <counts group_id="E3" events="5" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" events="9" subjects_affected="9" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eczema</sub_title>
                <counts group_id="E1" events="9" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="10" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Night sweats</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="8" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Seborrhoeic dermatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="9" subjects_affected="8" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dry skin</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermatitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermatitis contact</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin lesion</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="5" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Urticaria</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Intertrigo</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Photosensitivity reaction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rosacea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermatitis acneiform</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Psoriasis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash papular</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Actinic keratosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Drug eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dyshidrotic eczema</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eczema nummular</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Facial wasting</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Macule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Neurodermatitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pityriasis rosea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash macular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash pruritic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin fissures</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acne conglobata</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Acne cystic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Alopecia areata</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Angioedema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Cutaneous lupus erythematosus</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Dermatosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Eczema asteatotic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hidradenitis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hyperkeratosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lentigo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Lipoatrophy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Mechanical urticaria</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nail discolouration</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nail ridging</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pain of skin</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Papule</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Penile ulceration</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pityriasis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Post inflammatory pigmentation change</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Pruritus generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash erythematous</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash generalised</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Rash maculo-papular</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Scab</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin burning sensation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin exfoliation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin hyperpigmentation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin irritation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin mass</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin plaque</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Skin ulcer</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Spider naevus</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Swelling face</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Toxic skin eruption</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Vitiligo</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Xeroderma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Social circumstances</title>
            <event_list>
              <event>
                <sub_title>Stress at work</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Tooth extraction</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Inguinal hernia repair</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Nasal septal operation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Papilloma excision</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Tonsillectomy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="411"/>
                <counts group_id="E2" events="12" subjects_affected="12" subjects_at_risk="411"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Varicose vein</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Flushing</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="411"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Haematoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Hot flush</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Thrombophlebitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Circulatory collapse</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Deep vein thrombosis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
              <event>
                <sub_title>Phlebitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="411"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="411"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="338"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>GSK agreements may vary with individual investigators, but will not prohibit any investigator from publishing. GSK supports the publication of results from all centers of a multi-center trial but requests that reports based on single-site data not precede the primary publication of the entire clinical trial.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>GSK Response Center</name_or_title>
      <organization>GlaxoSmithKline</organization>
      <phone>866-435-7343</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

